ArticleMicrobial drug resistance (Larchmont, N.Y.)2017
Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City.
Article in Microbial drug resistance (Larchmont, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Optimized Amoxicillin Dosing is Associated with Higher Helicobacter pylori Eradication in Metabolic and Bariatric Surgery Candidates: A Retrospective Cohort Study.Obesity surgery · 2026Article
- Biofilm Formation and the Pore ProteinsAntibiotics (Basel, Switzerland) · 2026Article
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Multiplex PCR-Mass Spectrometry Mini-Sequencing Technology Detected Antibiotic Resistance ofInternational journal of molecular sciences · 2025Article
- Overcoming the effects of increasing antimicrobial resistance onExpert review of gastroenterology & hepatology · 2024Review
- Genetic Determinants of Clarithromycin and Fluoroquinolones Resistance inAntibiotics (Basel, Switzerland) · 2024Article
- Genetic Markers ofCurrent issues in molecular biology · 2024Article
- Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.Scientific reports · 2024Article
- The Prevalence, Risk Factors, and Antimicrobial Resistance Determinants ofInfectious disease reports · 2024Article
- Development and validation of next-generation sequencing panel for personalizedFrontiers in cellular and infection microbiology · 2024Article
- Molecular tools of antibiotic resistance forFrontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
- Molecular Characterization and Mutational Analysis of Clarithromycin- and Levofloxacin-Resistance Genes inInternational journal of molecular sciences · 2023Article
- Biofilm ofAntibiotics (Basel, Switzerland) · 2023Review
- Review
- Antibiotic Resistance in Selected Emerging Bacterial Foodborne Pathogens-An Issue of Concern?Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotic Resistance ofJournal of clinical medicine · 2023Article
- Levofloxacin+Tetracycline Quadruple Regimen for Eradication ofMiddle East journal of digestive diseases · 2023Article
- Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.Clinical microbiology reviews · 2022Review
- Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance fromBiomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Domain V of 23S rRNA, gyrA and gyrB Quinolones Resistance-Determining Region (QRDR), and pbp-1A gene point mutations were investigated in Helicobacter pylori-resistant isolates from three centres of Buenos Aires. Minimal inhibitory concentrations (MICs) were performed in 197 isolates from 52 H. pylori-positive naive patients by agar dilution method. Point mutations were achieved by amplification and sequencing of the target genes, and their association with resistance was determined by natural transformation assays. Resistance rates were as follows: metronidazole 28.8%, clarithromycin (CLA) 26.9%, levofloxacin (LEV) 32.7%, and amoxicillin (AMX) 7.6%. Nearly one-third of patients carried multidrug-resistant isolates. A2143G or A2142G in domain V of 23S-rRNA was found in all isolates showing high level of resistance to CLA (MIC >2 mg/L), accounting for 76.0% (38/50) of those with the resistant phenotype. The mutations A2267G or T1861C carried by 8/12 isolates with MIC 1-2 mg/L (low level) did not confer resistance by transformation. Substitutions at GyrA position 87 or 91, mainly N87K and D91G, were found in 92.8% (52/56) of the LEV-resistant isolates: 48 isolates with MIC 4-64 mg/L and 4/8 isolates with MIC 2 mg/L. The remaining four harboured K133N, also present in susceptible isolates. None of the substitutions in GyrB demonstrated to confer resistance. Transformation proved that PBP-1A N562Y and/or T556S substitutions confer the AMX resistance in our isolates, showing an additive effect. In conclusion, the usually reported mutations related to CLA, LEV, and AMX resistance were found in our isolates. However, low-level CLA resistance seems not to be due to mutations in Domain V of 23S rRNA gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.